Edition:
United States

Roche Holding AG (RO.S)

RO.S on Swiss Exchange

226.40CHF
11:31am EST
Change (% chg)

CHF-1.20 (-0.53%)
Prev Close
CHF227.60
Open
CHF227.20
Day's High
CHF228.40
Day's Low
CHF224.80
Volume
19,764
Avg. Vol
34,613
52-wk High
CHF271.75
52-wk Low
CHF219.80

Select another date:

Thu, Feb 15 2018

Photo

Roche to buy Flatiron Health for $1.9 billion to expand cancer care portfolio

Swiss drugmaker Roche Holding AG said on Thursday it would buy the rest of U.S. cancer data company Flatiron Health for $1.9 billion to speed development of cancer medicines and support its efforts to price them based on how well they work.

UPDATE 2-Roche to buy Flatiron Health for $1.9 bln to expand cancer care portfolio

Feb 15 Swiss drugmaker Roche Holding AG said on Thursday it would buy the rest of U.S. cancer data company Flatiron Health for $1.9 billion to speed development of cancer medicines and support its efforts to price them based on how well they work.

Roche to buy Flatiron Health for $1.9 bln

Feb 15 Drugmaker Roche Holding AG said on Thursday it would buy the rest of the privately held oncology data company Flatiron Health Inc for $1.9 billion to speed up development and delivery of breakthrough medicines for cancer patients.

BRIEF-Roche To Acquire Flatiron Health

* ROCHE SAYS UNDER TERMS OF THE AGREEMENT, ROCHE WILL MAKE A PAYMENT OF $1.9 BILLION TO FLATIRON HEALTH ON A FULLY DILUTED BASIS

BRIEF-Health Canada Approves Roche's Ocrevus For Type of Multiple Sclerosis

* HEALTH CANADA APPROVES OCREVUS® (OCRELIZUMAB) FOR CANADIANS LIVING WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS)

BRIEF-Shire says too early to see impact Of Roche competitor Hemlibra

* CFO SAYS SEES IT IS STILL EARLY TO ASSESS IMPACT OF COMPETITOR ROCHE'S HEMLIBRA ON HEMOPHILIA FRANCHISE Further company coverage: (Reporting By London Bureau)

BRIEF-Roche Receives FDA Clearance For Factor Ii And Factor V Test On The Cobas® 4800 System

* ROCHE RECEIVES FDA CLEARANCE FOR FACTOR II AND FACTOR V TEST ON THE COBAS® 4800 SYSTEM Source text for Eikon: Further company coverage:

Drug copies ready to take next bite out of Roche's cancer sales

LONDON European oncologists will soon get their hands on cut-price copies of breast cancer drug Herceptin, turning the screws on maker Roche and giving another boost to a new breed of companies focused on so-called biosimilars.

Drug copies ready to take next bite out of Roche's cancer sales

LONDON, Feb 13 European oncologists will soon get their hands on cut-price copies of breast cancer drug Herceptin, turning the screws on maker Roche and giving another boost to a new breed of companies focused on so-called biosimilars.

Roche wins UK watchdog's nod for lymphoma drug after initial snub

ZURICH Britain's healthcare watchdog (NICE) recommended Roche's medicine Gazyvaro for previously untreated advanced follicular lymphoma patients after initially rejecting the Swiss drugmaker's medicine last year as too expensive.

Select another date: